World Colorectal Cancer Day
Yesterday was World Colorectal Cancer Day, the most frequent tumor in the Spanish Population and the second cause of cancer death worldwide, leading to almost 1 million deaths per year. …
Today is World Cancer Day
World Cancer Day aims to prevent millions of deaths each year by raising awareness and education about cancer, and pressing governments and individuals across the world to take action against …
Aniling participates in the virtual DISRUPTOUR program
We are happy to announce that Aniling has been selected to participate in the virtual immersion in the Silicon Valley health and entrepreneurship ecosystem (DISRUPTOUR). This great initiative, organized by …
NGS Technologist open position
Our close collaborator, Germans Trias i Pujol Research Institute (IGTP), is hiring. IGTP is looking for a highly motivated NGS Technologist. The call for applications will close on October 31th …
Aniling has participated in the “Matchmaking en Diagnóstico in Vitro: Un impulso a la cadena de valor en salud”
Aniling has participated in the “Matchmaking en Diagnóstico in Vitro: Un impulso a la cadena de valor en salud”. Llorenç Coll, CEO at Aniling, had the opportunity for pitching and …
Aniling has attended The Investment Readiness Series (Medtech Edition)
Aniling had a great time in The Investment Readiness Series (Medtech Edition). Thanks Biocat to bring together investors and startups and increase the deal flow of projects ready for investment.
Aniling has presented GEUS-CLL and GEUS-CRC in the Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology
Aniling has attended “The Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology” organized by the Cell Press and the National Cancer Institute (NCI). Sheila Santín has presented the advances of …
Aniling has presented GEUS-CLL in the International Workshop of Chronic Lymphocytic Leukemia (iwCLL2021)
Aniling has attended to the International Workshop of Chronic Lymphocytic Leukemia (iwCLL2021), the biennial international meeting committed to advancing the field of CLL. Ester Cuenca has presented the advances of …
Aniling has reached the CE Mark for GEUS-CLL
We are very proud to announce that Aniling has reached the CE Mark for our first product, GEUS-CLL, a first-in-class IVD medical device to support the diagnosis, prognosis, treatment selection …
Aniling is validating GEUS-LB, a molecular diagnostic test for liquid biopsy
Liquid biopsy tests provide access to tumor DNA in a minimally invasive way, offering great potential in oncology applications, including precision medicine, early cancer diagnosis and disease’s follow-up and monitoring. At Aniling, we have developed a new product, GEUS-LB, targeting …